Why the study?
Does percutaneous administration of oestradiol-17 beta alter serum oestrogen levels compared to oral administration in post-menopausal women and men?
Does percutaneous administration of oestradiol-17 beta alter serum oestrogen levels compared to oral administration in post-menopausal women and men?
Percutaneous administration of oestradiol-17 beta provides a slower, sustained increase in serum oestrogens with less oestrone conversion compared to oral administration, potentially avoiding first-pass hepatic metabolism.
May support percutaneous oestradiol to avoid first-pass hepatic effects in postmenopausal women; leaves open impacts on clinical outcomes versus oral routes.
Equivalent doses of oestradiol-17 beta were given orally and percutaneously to eight post-menopausal women and three men. The resultant serum levels of unconjugated immunoreactive oestrogens and total oestrone were followed during 48 hours after hormone administration. A single percutaneous dose of 4 mg oestradiol-17 beta resulted in increased serum levels of oestradiol-17 beta in all individuals. Compared to oral administration the increase in serum oestrogen levels was quite slow and they were maintained for 48 hours. In contrast to the rapid and very marked increase in serum total oestrone following oral administration of oestradiol-17 beta, only a moderate increase was obtained after percutaneous administration and there was a tendency to a biphasic pattern. Topical administration of oestradiol-17 beta might have physiological advantages as the steroid will reach the peripheral circulation without passing the entero-hepatic circulation.
No takes yet. Share an insight, caveat, or question.
Lyrenäs et al. (1981) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: